When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
There have been many advancements in chemotherapy and immunotherapy treatments for various cancers over the past decade, but the 5-year relative survival rate for glioblastoma patients is still…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
March is Colorectal Cancer Awareness Month. In this installment of 60-Second Symposia, Dr. Lynn O’Connor briefly outlines some statistics and information about colon and rectum cancer that you…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
The standard of care for pancreatic cancer has remained largely unchanged for the past two decades, but now scientists have identified 10 different genetic pathways driving the disease,…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
